Table 3 Odds ratios and 95% confidence intervals from logistic regression model comparing women who received hormone therapy (in addition to surgical therapy) to women who received no hormone therapy
From: Treatment patterns for ductal carcinoma in situ from 2000–2010 across six integrated health plans
No hormone therapy (N = 6812) | Hormone therapy (N = 2625) | |
|---|---|---|
KP region | ||
1 | 1.0 | 1.29 (1.08-1.55) |
2 | 1.0 | 1.21 (0.93-1.58) |
3 | 1.0 | 1.14 (0.87-1.49) |
4 | Referent | |
5 | 1.0 | 0.96 (0.78-1.19) |
6 | 1.0 | 0.97 (0.87-1.07) |
Age at diagnosis | ||
< 50 years | Referent | |
50-59 years | 1.0 | 1.11 (0.98-1.25) |
60-69 years | 1.0 | 0.88 (0.77-1.00) |
70+ years | 1.0 | 0.65 (0.56-0.76) |
Race/Ethnicity | ||
White | Referent | |
African American | 1.0 | 0.82 (0.70-0.96) |
Asian | 1.0 | 1.18 (1.03-1.34) |
Hispanic | 1.0 | 1.20 (1.02-1.40) |
Census Tract % College Educated (Quintiles) | ||
1: 32.3% - 78.8% | 1.0 | 1.03 (0.89-1.18) |
2: 78.9% - 86.3% | 1.0 | 1.02 (0.88-1.18) |
3: 86.5% - 92.2% | 1.0 | 0.96 (0.83-1.11) |
4: 92.3% - 95.7% | 1.0 | 0.81 (0.69-0.94) |
5 (highest): > 95.7% | Referent | |
Year of Diagnosis | 1.0 | 0.99 (0.97-1.00) |
Comorbidity Index | ||
0 | Referent | |
1 | 1.0 | 1.22 (1.09-1.38) |
2+ | 1.0 | 0.76 (0.64-0.91) |
Nuclear Grade | ||
Low/Intermediate | Referent | |
High | 1.0 | 0.83 (0.76-0.92) |
Unknown | 1.0 | 0.89 (0.77-1.05) |